ArticleProceedings of the National Academy of Sciences of the United States of America2014
Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 73 citations in OpenAlex.
- Hormesis and hydra effects revealed by intraspecific overcompensation models and dose-response curves.Journal of the Royal Society, Interface · 2025Article
- Dose Considerations for Vaccinia Oncolytic Virus Based on Retrospective Reanalysis of Early and Late Clinical Trials.Vaccines · 2024Article
- Characterization of an Aptamer Targeting Neu5Gc, as an Endogenous Pathogenic Factor Derived from Red Meat.Molecules (Basel, Switzerland) · 2024Article
- A systematic review reveals conflicting evidence for the prevalence of antibodies against the sialic acid 'xenoautoantigen' Neu5Gc in humans and the need for a standardised approach to quantification.Frontiers in molecular biosciences · 2024Review
- Hormetic and synergistic effects of cancer treatments revealed by modelling combinations of radio - or chemotherapy with immunotherapy.BMC cancer · 2023Article
- Article
- Discrimination between sialic acid linkage modes using sialyllactose-imprinted polymers.RSC advances · 2021Article
- Combinatorial Design of a Sialic Acid-Imprinted Binding Site.ACS omega · 2021Article
- The tumor-promoting effects of the adaptive immune system: a cause of hyperprogressive disease in cancer?Cellular and molecular life sciences : CMLS · 2021Review
- Association between Neu5Gc carbohydrate and serum antibodies against it provides the molecular link to cancer: French NutriNet-Santé study.BMC medicine · 2020Article
- Tumor-associated macrophages in classical Hodgkin lymphoma: hormetic relationship to outcome.Scientific reports · 2020Article
- Reply to Soulillou et al.: Difficulties in extrapolating from animal models exemplify unusual human atherosclerosis susceptibility and mechanisms viaProceedings of the National Academy of Sciences of the United States of America · 2020Article
- Enhanced Pro-apoptotic Effects of Fe(II)-Modified IVIG on Human Neutrophils.Frontiers in immunology · 2020Article
- Contribution of Fcγ receptor IIB to creating a suppressive tumor microenvironment in a mouse model.Cancer immunology, immunotherapy : CII · 2019Article
- A general model of hormesis in biological systems and its application to pest management.Journal of the Royal Society, Interface · 2019Article
- Differential Recognition of Diet-Derived Neu5Gc-Neoantigens on Glycan Microarrays by Carbohydrate-Specific Pooled Human IgG and IgA Antibodies.Bioconjugate chemistry · 2019Article
- Article
- Presentation Mode of Glycans Affect Recognition of Human Serum anti-Neu5Gc IgG Antibodies.Bioconjugate chemistry · 2019Article
- From "Serum Sickness" to "Xenosialitis": Past, Present, and Future Significance of the Non-human Sialic Acid Neu5Gc.Frontiers in immunology · 2019Review
- Evolution of sialic acids: Implications in xenotransplant biology.Xenotransplantation · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
Compelling evidence for naturally occurring immunosurveillance against malignancies informs and justifies some current approaches toward cancer immunotherapy. However, some types of immune reactions have also been shown to facilitate tumor progression. For example, our previous studies showed that although experimental tumor growth is enhanced by low levels of circulating antibodies directed against the nonhuman sialic acid N-glycolyl-neuraminic acid (Neu5Gc), which accumulates in human tumors, growth could be inhibited by anti-Neu5Gc antibodies from a different source, in a different model. However, it remains generally unclear whether the immune responses that mediate cancer immunosurveillance vs. those responsible for inflammatory facilitation are qualitatively and/or quantitatively distinct. Here, we address this question using multiple murine tumor growth models in which polyclonal antibodies against tumor antigens, such as Neu5Gc, can alter tumor progression. We found that although growth was stimulated at low antibody doses, it was inhibited by high doses, over a linear and remarkably narrow range, defining an immune response curve (IRC; i.e., inverse hormesis). Moreover, modulation of immune responses against the tumor by altering antibody avidity or by enhancing innate immunity shifted the IRC in the appropriate direction. Thus, the dualistic role of immunosurveillance vs. inflammation in modulating tumor progression can be quantitatively distinguished in multiple model systems, and can occur over a remarkably narrow range. Similar findings were made in a human tumor xenograft model using a narrow range of doses of a monoclonal antibody currently in clinical use. These findings may have implications for the etiology, prevention, and treatment of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.